UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus ... a topical phosphodiesterase 4 (PDE-4) inhibitor for atopic dermatitis already sold as ...